Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Mesa Biotech to Present at Next Generation Diagnostics Summit

Mesa Biotech Inc.
Posted on: 22 Aug 16

PR Newswire

SAN DIEGO, Aug. 22, 2016

SAN DIEGO, Aug. 22, 2016 /PRNewswire/ -- Mesa Biotech Inc., a privately-held, molecular diagnostic company that has developed a testing platform designed specifically for point-of-care (POC) infectious disease diagnosis, today announced that it will unveil its novel point-of-care molecular diagnostic system at the eighth annual Next Generation Dx Summit to be held August 22 – 25 at the Grand Hyatt in Washington, DC. In a platform presentation on Wednesday August 24th entitled"Finally, a Point-of-Care Molecular System for the Physician's Office" Emily Winn-Deen, Ph.D., Chief Strategy Officer, Mesa Biotech, Inc. will describe the new testing system, which will also be available for meeting attendees to preview in the company's exhibit booth. The system, which is currently for investigational use only, will be launched for sale in Europe in the spring of 2017.

"This summit's theme of 'moving assays to the clinic' is a great fit for us," said Emily Winn-Deen, Chief Strategy Officer, Mesa Biotech, Inc. "Mesa Biotech is breaking diagnostic barriers by making highly advanced, accurate, laboratory quality molecular testing available to all levels of healthcare providers in a portable, easy-to-use, affordable POC system."  

About Mesa Biotech Inc.

Mesa Biotech is an emerging molecular diagnostic company, bringing the superior diagnostic performance of nucleic acid amplification to the point-of-care (POC). Mesa Biotech's diagnostic system consists of a portable, palm-sized dock and a disposable, assay-specific test cassette. This patented system will allow healthcare professionals to obtain actionable, laboratory-quality results at the POC in 30 minutes or less with greater sensitivity and specificity than many current infectious disease rapid immunodiagnostic tests. Mesa's technology development has been funded to date by a series of grants and private equity investments totaling approximately $30 million. The company is preparing for Series A funding in 2016 and expects to obtain FDA approval for its first product, an influenza assay and dock, in 2017.  For more information visit


To view the original version on PR Newswire, visit:

SOURCE Mesa Biotech Inc.

PR Newswire

Last updated on: 22/08/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.